Results 61 to 70 of about 3,076,808 (309)

Which Measure of Stone Burden is the Best Predictor of Interventional Outcomes in Urolithiasis: A Systematic Review and Meta-analysis by the YAU Urolithiasis Working Group and EAU Urolithiasis Guidelines Panel

European Urology Open Science
Background and objective: Stone size has traditionally been measured in one dimension. This is reflected in most of the literature and in the EAU guidelines.
Robert Geraghty, Amelia Pietropaolo, Lazaros Tzelves, Riccardo Lombardo, Helene Jung, Andreas Neisius, Ales Petrik, Bhaskar K. Somani, Niall F. Davis, Giovanni Gambaro, Romain Boissier, Andreas Skolarikos, Thomas Tailly   +12 more
doaj   +1 more source

Sore Throat Treatment Guidelines are Fanning the Flames of Antimicrobial Resistance [PDF]

, 2020
Martin Duerden, Duerden, M Gulliford, G Worrall, G Coutinho, D Watkins, A Cassini   +6 more
openalex   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage [PDF]

, 2006
Eric Jauniaux
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Rationing cancer treatment: a qualitative study of perceptions of legitimate limit-setting

BMC Health Services Research, 2018
Background Governments are facing tough choices about whether to fund new, promising but highly expensive drugs within the public healthcare system. Decisions that some drugs are not sufficiently beneficial relative to their cost to merit public funding ...
Eli Feiring, Hege Wang
doaj   +1 more source

Quality Improvement Guidelines for Mesenteric Angioplasty and Stent Placement for the Treatment of Chronic Mesenteric Ischemia [PDF]

, 2018
Anil K. Pillai, Sanjeeva P. Kalva, Steven Hsu, T.G. Walker, James E. Silberzweig, Ganesan Annamalai, Mark O. Baerlocher, Jason Mitchell, Mehran Midia, Boris Nikolic, Sean R. Dariushnia, T.G. Walker, James E. Silberzweig, Boris Nikolic, Gunjan Aeron, J.F. Angle, Ronald S. Arellano, Sriharsha Athreya, Mark O. Baerlocher, Stephen Balter, Kevin M. Baskin, Ian Brennan, Olga R. Brook, Daniel B. Brown, Drew M. Caplin, Michael L. Censullo, Abbas Chamsuddin, Christine P. Chao, Mandeep Dagli, Jon Davidson, A. Michael Devane, Eduardo Eyheremendy, Florian J. Fintelmann, Joseph J. Gemmete, Vyacheslav Gendel, Jennifer E. Gould, Tara Graham, John A. Hancock, Mark Hogan, Eric J. Hohenwalter, Bertrand Janne d’Othée, Arshad Khan, Hyun S. Kim, Maureen P. Kohi, Christy Lee, N. Mani, G Martinez-Salazar, J. Kevin McGraw, Philip M. Meyers, Donald L. Miller, Christopher S. Morris, Indravadan Patel, Anil K. Pillai, Uei Pua, Ellen Redstone, Anne C. Roberts, Wael E. Saad, Tarun Sabharwal, Marc Sapoval, Brian J. Schiro, Samir S. Shah, Paul B. Shyn, Siddharth A. Padia, Nasir H. Siddiqi, James E. Silberzweig, LeAnn S. Stokes, Rajeev Suri, Ulku C. Turba, Aradhana M. Venkatesan, Jeffrey L. Weinstein   +69 more
openalex   +1 more source

Guidelines, guidelines, guidelines! [PDF]

Post Reproductive Health, 2016
Heather, Currie, Eddie, Morris, Paul, Simpson   +2 more
openaire   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Decision letter for "Guidelines for standardizing T cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes"

, 2021

openalex   +1 more source